Immunovant (IMVT) Change in Accured Expenses (2019 - 2026)

Immunovant (IMVT) has 7 years of Change in Accured Expenses data on file, last reported at $1.6 million in Q1 2025.

• Quarterly Change in Accured Expenses fell 89.35% year-over-year to $1.6 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $8.9 million (up 561.45% YoY) and the FY2026 annual result came in at $45.0 million, up 404.31% from the prior year.
• Change in Accured Expenses retreated to $1.6 million in Q1 2025, from $4.1 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $15.5 million in Q1 2024 to a low of -$17.3 million in Q2 2023.
• A 5-year average of $2.2 million and a median of $2.6 million in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 573.27% — and 2023, when it surged 312.78%.
• Tracing IMVT's Change in Accured Expenses over 5 years: stood at $8.3 million in 2021, then plunged by 68.21% to $2.6 million in 2022, then plunged by 302.77% to -$5.3 million in 2023, then jumped by 177.6% to $4.1 million in 2024, then sank by 60.27% to $1.6 million in 2025.
• The last three Change in Accured Expenses figures came in at $1.6 million (Q1 2025), $4.1 million (Q4 2024), and $10.7 million (Q3 2024), per Business Quant data.